dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Turner, N. C. |
dc.contributor.author | Alarcón, E. |
dc.contributor.author | Armstrong, A. C. |
dc.contributor.author | Philco, M. |
dc.contributor.author | López Chuken, Y. A. |
dc.contributor.author | Sablin, Marie-Paule |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.date.accessioned | 2021-03-16T09:36:56Z |
dc.date.available | 2021-03-16T09:36:56Z |
dc.date.issued | 2019-05-01 |
dc.identifier.citation | Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, et al. BEECH: A dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA. Ann Oncol. 2019 May 1;30(5):774–80. |
dc.identifier.issn | 1569-8041 |
dc.identifier.uri | https://hdl.handle.net/11351/5759 |
dc.description | Inhibidor de l'AKT; PIK3CA; Capivasertib |
dc.description.sponsorship | This study was supported by AstraZeneca (no grant number applies). |
dc.language.iso | eng |
dc.publisher | Oxford University Press |
dc.relation.ispartofseries | Annals of Oncology;30(5) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Estrògens - Receptors |
dc.subject | Metàstasi |
dc.subject | Mama - Càncer - Tractament |
dc.subject.mesh | Neoplasm Metastasis |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Receptors, Estrogen |
dc.title | BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1093/annonc/mdz086 |
dc.subject.decs | metástasis neoplásica |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | receptores de estrógenos |
dc.relation.publishversion | https://www.annalsofoncology.org/article/S0923-7534(19)31171-8/fulltext |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Turner NC] Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK. Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. [Alarcón E] Clinical Oncology Department, British American Hospital, Lima, Peru. [Armstrong AC] Department of Medical Oncology, Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. [Philco M] Peruvian Institute of Oncology Radiotherapy, Lima, Peru. [López Chuken YA] University Hospital, Monterrey, Mexico. [Sablin MP] Department of Drug Development and Innovation (D3i), Curie Institute, Paris, France. [Oliveira, M] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 30860570 |
dc.identifier.wos | 000482490300013 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |